基于合作发明专利的我国生物医药领域研发合作现状分析

Status Quo Analysis on R&D Cooperation in Biomedical Field in China Based on Invention Co-patent

目的:为促进我国生物医药领域研发合作提出建议。方法:从专利数据库中检索2000-2015年生物医药领域全部合作发明专利的信息,收集年份、专利名称、申请号、申请人、专利地址等信息,并进行描述性统计分析。结果:生物医药领域合作发明专利数量呈逐年上升趋势,2015年的合作发明专利数量大约是2000年的9倍;合作发明专利主要来自北京、上海、广东,占49.1%;数量排名前15位的申请人共拥有983件合作发明专利,占全部合作专利数的8.9%,其中7位为企业申请人;在2014年国内生产总值排名前10位的城市所申请的合作发明专利中,企业、科研机构(包括医院)和高校之间共同申请的发明专利占全部专利数的56.2%。结论:我国生物医药研发合作主要集中于少数发达省份和城市,合作发明专利的集中度不高;研发合作主要以企业为主导,医院参与度较低。政府应建立全国性的生物医药信息分享平台,加强大型医药企业研发合作的意识,鼓励医院积极参与生物医药研发合作活动。

OBJECTIVE：To put forward relevant suggestions for promoting the RD cooperation in biomedical field in China.METHODS：Information of all invention co-patents in biomedical fields during 2000-2015 in patent database was collected,including year,patent name,application number,applicant,patent address,etc.,and descriptive statistical analysis was conducted. RESULTS：The number of invention co-patents in biomedical fields had been increasing year by year,and the number of invention copatents in 2015 was about 9 times than that in 2000. Invention co-patents mainly came from Beijing,Shanghai and Guangdong,ac-counting for 49.1%. The top 15 applicants had 983 invention co-patents in total,accounting for 8.9% of the total number of co-patents,7 of which were enterprises. And in the invention co-patents applied by the top 10 cities for GDP ranking in 2014,invention co-patents applied by enterprises,scientific research institutions（include hospitals）and universities accounted for 56.2% of all patents. CONCLUSIONS：The RD cooperation in biomedical fields has mainly focused on a few developed provinces and cities,with low concentration of invention co-patents;the RD cooperation is mainly led by enterprises,and hospitals have low participation. The government should establish national biomedical information sharing platform,raise the RD cooperation awareness of large-scale pharmaceutical enterprises and encourage hospitals to actively participate in RD cooperation activities in biomedicine fields.